关节炎患者接种一剂肺炎球菌结合疫苗后长达10年严重肺炎球菌感染风险降低
研究纳入595例成年关节炎患者(类风湿关节炎342例,脊柱关节病253例)接种一剂7价肺炎球菌结合疫苗(PCV7),并与匹配的未接种参照者比较。结果显示接种的类风湿关节炎和脊柱关节病患者肺炎及所有严重感染的相对风险分别显著降低53%和46%,接种后至首次肺炎或所有严重感染的时间与参照者无显著差异。作者认为一剂PCV7可能降低接受免疫调节治疗的关节炎患者长达10年的严重肺炎球菌感染风险。
要点
- 接种PCV7的类风湿关节炎和脊柱关节病患者肺炎相对风险降低53%,所有严重感染相对风险降低46%。
- 接种后至首次肺炎或所有严重感染的时间在患者与参照者间无显著差异。
- 较高年龄、类风湿关节炎诊断和合并使用泼尼松龙与感染相关。
核心结论
- 一剂肺炎球菌结合疫苗可能降低接受免疫调节治疗的关节炎患者长达10年的严重肺炎球菌感染风险。
研究设计与样本
- 研究纳入595例成年关节炎患者(类风湿关节炎342例,女性占80%;脊柱关节病253例,女性占45%),均接种一剂PCV7。
- 类风湿关节炎患者平均年龄62岁、平均病程16年;脊柱关节病患者平均年龄51岁、平均病程14年。
- 每例患者匹配4名参照者。
- 接种时420例患者使用bDMARD(抗TNF 330例、托珠单抗15例、阿巴西普18例、阿那白滞素1例、利妥昔单抗56例)。
- 甲氨蝶呤单药治疗86例,与bDMARD联合治疗220例;89例脊柱关节病患者使用NSAIDs而未用DMARD。
主要发现
- 接种的类风湿关节炎和脊柱关节病患者肺炎相对风险显著降低53%,所有严重感染相对风险显著降低46%。
- 接种后至首次肺炎或所有严重感染的时间在患者与参照者间无显著差异。
- 较高年龄、类风湿关节炎诊断和合并使用泼尼松龙与感染相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: To examine rates of serious pneumococcal infections up to 10 years after vaccination with 7-valent conjugated pneumococcal vaccine (PCV7) in patients with arthritis compared to non-vaccinated arthritis patients. METHODS: In total, 595 adult arthritis patients (rheumatoid arthritis; RA = 342, 80 % women and spondylarthropathy; SpA = 253, 45 % women) received one dose of PCV7. Mean age/disease duration were 62/16 and 51/14 years, respectively. For each patient, 4 matched reference subjects were identified. At vaccination, 420 patients received bDMARDs (anti-TNF = 330, tocilizumab = 15, abatacept = 18, anakinra = 1, rituximab = 56). Methotrexate was given as monotherapy (n = 86) or in combination with bDMARD (n = 220). 89 SpA patients received NSAIDs without DMARD. The Skåne Healthcare Register was searched for ICD-10 diagnostic codes for pneumococcal infections (pneumonia, lower respiratory tract infection, septicemia, meningitis, septic arthritis) between January 2000 and December 2018. Frequency of infections after vs before vaccination were calculated (relative risks). Relative risk ratio (RRR) and relative risk reduction (1-RRR) were calculated comparing patients vs non-vaccinated references. Kaplan-Meier and Cox regression were used to investigate time to first event and predictors of infections. RESULTS: Among vaccinated RA and SpA patients, there was a significant relative risk reduction of pneumonia and all serious infections; 53% and 46%, respectively. There was no significant difference in time to first pneumonia or all serious infections after vaccination between patients and references. Higher age, RA diagnosis and concomitant prednisolone were associated with infections. CONCLUSION: One dose of pneumococcal conjugate vaccine may decrease risk of serious pneumococcal infection up to 10 years in patients with arthritis receiving immunomodulating treatment.
引用
- Nagel J, Jönsson G, Nilsson JÅ, et al. Reduced risk of serious pneumococcal infections up to 10 years after a dose of pneumococcal conjugate vaccine in established arthritis. Vaccine. 2022. PMID: 36496283. doi:10.1016/j.vaccine.2022.11.075
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。